-
Zai Lab’s Repotrectinib Targets Breakthrough Therapy Designation for TRK-Positive Tumors
•
The Center for Drug Evaluation (CDE) website has indicated that repotrectinib, a next-generation ROS1/TRK/ALK tyrosine kinase inhibitor (TKI) licensed by China-based biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB), is on track to receive breakthrough therapy designation (BTD) status in China for the treatment of NTRK fusion-positive advanced solid tumors that…
-
Hangzhou Minsheng Healthcare Aims to Raise RMB890 Million in Shenzhen GEM IPO
•
Hangzhou Minsheng Healthcare Co., Ltd. (SHE: 301507) is poised to raise RMB890 million through an initial public offering (IPO) on the Shenzhen Growth Enterprise Market (GEM). The company plans to issue 89 million shares at a price of RMB10 per share, with the ticker symbol set as 301507. Road Show…
-
RemeGen’s Telitacicept Shows Positive Phase III Results in Rheumatoid Arthritis Study
•
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has announced positive results from the China Phase III clinical study for its telitacicept in the treatment of rheumatoid arthritis (RA). Following these results, the company has submitted a supplementary New Drug Application (sNDA) to the Center for Drug Evaluation (CDE). Previously,…
-
Shanxi Jinbo Bio-pharmaceutical Plans Fundraise with Private Placement and IPO Proceeds
•
China-based Shanxi Jinbo Bio-pharmaceutical Co., Ltd. (832982.BSE) is poised to raise RMB 36.75 million through a private placement on the Beijing Stock Exchange, supplementing the RMB 245 million initial public offering (IPO) proceeds the company recently acquired. Jinbo Bio’s Industrialization of Recombinant Collagen ProteinFounded in 2008, Jinbo Bio has achieved…
-
CCDI Cartoon Exposes “Prescription Data Rebates” Corruption in China’s Healthcare System
•
China’s Central Commission for Discipline Inspection (CCDI), the country’s anti-graft bureau, has released a cartoon short film titled “Corruption and Irregular Practices in the Medical Field – Cutting the ‘Prescription Data Rebates’ Chain”. The film sheds light on the current methods used by doctors within China’s healthcare system to generate…
-
Roche Subsidiary Genentech Addresses Accidental Disclosure of Tiragolumab Trial Data
•
Swiss pharmaceutical major Roche (SWX: ROG), through its subsidiary Genentech, has released a statement addressing an accidental disclosure of the second interim analysis from an ongoing Phase III study. The study involves the anti-TIGIT biologic tiragolumab, used with and without the PD-L1 inhibitor Tecentriq (atezolizumab), for patients with PD-L1-high locally…
-
Shanghai Updates Biomedical R&D Import Pilot for Streamlined Customs Clearance
•
The Shanghai Municipal Commission of Commerce, in collaboration with Shanghai Customs and the Shanghai Municipal Medical Products Administration, has released an updated version of the “Shanghai Municipal Biomedical R&D Items Import Pilot.” The revised program, effective from August 1, 2023, through July 31, 2025, aims to expedite the market entry…
-
Bayer Partners with Mahana Therapeutics to Market Digital Health Technologies
•
Germany-headquartered Bayer (ETR: BAYN) has announced a strategic partnership with US digital developer Mahana Therapeutics. The collaboration focuses on the distribution and marketing of Mahana’s digital technologies, further expanding Bayer’s foray into the digital health sector. This move follows Bayer’s launch earlier this year of a precision health product development…
